AvidBiotics Creates Novel Proteins that Kill Bacteria on the Farm, in the Lab, in the Body
By: Luke Timmerman | Source: XConomy.com
Dave Martin is one of the people in biotech who has truly seen it all. In the ’80s, the industry’s early days, he was head of R&D at Genentech. His latest passion, which he’s pursuing with business partner Jim Knighton, is taking shape at a lean startup in South San Francisco called AvidBiotics.
Read or purchase full article from: XConomy.com
Press Releases
Pylum Biosciences Collaborates on Research Published in the Journal Nature
AvidBiotics’ Scientists Co-author Publication in Science Translational Medicine Describing A New Class of Targeted Antibacterial Agents for Clostridium difficile
Study Published in mBio Shows that Avidocin™ Proteins Prevent Clostridium Difficile Infection in Mice without Harming Protective Gut Bacteria
AvidBiotics Granted U.S. Patent for Bactericidal Proteins that Selectively Kill C. Difficile
AvidBiotics Awarded SBIR Grant for Avidocin™ Antibacterial Proteins Against Clostridium difficile
Articles